Gut Liver.
2016 Nov;10(6):910-916. 10.5009/gnl15537.
The Benefits of Combination Therapy with Esomeprazole and Rebamipide in Symptom Improvement in Reflux Esophagitis: An International Multicenter Study
- Affiliations
-
- 1Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine, Bucheon, Korea.
- 2Department of Internal Medicine, The Catholic University of Korea College of Medicine, Seoul, Korea. psheon5132@naver.com
- 3Department of Internal Medicine, Inje University Seoul Paik Hospital, Inje University College of Medicine, Seoul, Korea.
- 4Department of Internal Medicine, Hallym University College of Medicine, Seoul, Korea.
- 5Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea.
- 6Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
- 7Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
- 8Department of Internal Medicine, Kyung Hee University School of Medicine, Seoul, Korea.
- 9Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
- 10Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea.
- 11Department of Internal Medicine, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, Korea.
- 12Department of Preventive Medicine, Soonchunhyang University College of Medicine, Cheonan, Korea.
- 13Department of Gastroenterology, The First Affiliated Hospital, Anhui Medical University, Hefei, China.
- 14Department of Gastroenterology and Hepatology, General Hospital, Tianjin Medical University, Tianjin, China.
- 15Department of Gastroenterology, The Second Affiliated Hospital and Yuying Children's Hospital, Wenzhou Medical University, Shanghi, China.
- 16Department of Gastroenterology, Shanghai East Hospital, Tongji University, Shanghi, China.
- 17Department of Gastroenterology, Ruijin Hospital, Shanghai Jiaotong University, Shanghi, China.
- 18Department of Internal Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
- 19Department of Internal Medicine, University of Santo Tomas Hospital, Manila, Philippines.
- KMID: 2412096
- DOI: http://doi.org/10.5009/gnl15537
Abstract
- BACKGROUND/AIMS
To investigate the effects of esomeprazole and rebamipide combination therapy on symptomatic improvement in patients with reflux esophagitis.
METHODS
A total of 501 patients with reflux esophagitis were randomized into one of the following two treatment regimens: 40 mg esomeprazole plus 300 mg rebamipide daily (combination therapy group) or 40 mg esomeprazole daily (monotherapy group). We used a symptom questionnaire that evaluated heartburn, acid regurgitation, and four upper gastrointestinal symptoms. The primary efficacy end point was the mean decrease in the total symptom score.
RESULTS
The mean decreases in the total symptom score at 4 weeks were estimated to be −18.1±13.8 in the combination therapy group and −15.1±11.9 in the monotherapy group (p=0.011). Changes in reflux symptoms from baseline after 4 weeks of treatment were −8.4±6.6 in the combination therapy group and −6.8±5.9 in the monotherapy group (p=0.009).
CONCLUSIONS
Over a 4-week treatment course, esomeprazole and rebamipide combination therapy was more effective in decreasing the symptoms of reflux esophagitis than esomeprazole monotherapy.
Keyword
MeSH Terms
-
Adult
Alanine/administration & dosage/*analogs & derivatives
Drug Administration Schedule
Drug Therapy, Combination
Esomeprazole/*administration & dosage
Esophagitis, Peptic/*drug therapy
Female
Humans
Male
Middle Aged
Prospective Studies
Proton Pump Inhibitors/*administration & dosage
Quinolones/*administration & dosage
Severity of Illness Index
Treatment Outcome
Proton Pump Inhibitors
Quinolones
Esomeprazole
Alanine
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Multicenter Study to Evaluate the Effect of Esomeprozole in Gastro-esophageal Reflux Disease
- A Double-blind, Randomized, Multicenter Clinical Trial Investigating the Efficacy and Safety of Esomeprazole Single Therapy Versus Mosapride and Esomeprazole Combined Therapy in Patients with Esophageal Reflux Disease
- The Effect of Esomeprazole 40 mg Single Therapy in Patients with Non-Erosive Reflux Disease Who Are Resistant to Standard-Dose Proton Pump Inhibitor Therapy: An Open-Label Multicenter Study
- Minimal Change Esophagitis
- The Efficacy of Short-term Administration of Revaprazan on Gastroesophageal Reflux Symptoms: Comparison with Half Dose Esomeprazole, a Pilot Study
